TXN-A
/ Txinno Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Discovery and characterization of TXN-A: A first-in-class, orally bioavailable ULK1 degrader with high selectivity and potency for TNBC treatment
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Oncology • Triple Negative Breast Cancer • ULK1
1 to 1
Of
1
Go to page
1